Name: Latest research reports of Ipca Laboratories Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Phillip Capital

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Expensive Performer

1460.0000 17.20 (1.19%)

NSE May 23, 2025 15:31 PM

38.78% Gain from 52W Low

Volume: 124.6K

Ipca Laboratories Ltd.

11 Apr 2016

1460.00

1.19%

IPCA Co Update 11April2016

Buy: Ipca Laboratories Ltd.

Target

Phillip Capital

any volume of Artemisininbased Combination Therapy (ACTs) to IPCA, considering the continuingUSFDAimportbanonIPCA'splants.Wehadbuiltascenarioofnormalcyinthis supply,startingQ1FY17.Withnoorderallocation,IPCAwouldseeadverserevenueimpact...

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.